Table 3. Clinical characteristics between intravenous GCV and oral VGCV.

	Intravenous GCV (n = 61)	Oral VGCV (n = 22)	P-value
White blood cells (/ul)	6,550 (1,280–27,360)	7,430 (2,410–14,750)	0.871
Hemoglobin (g/dL)	9.1 (4.0–15.9)	10.8 (8.2–14.1)	0.003
Platelet (/ul)	108,500 (21,000–465,000)	155,000 (39,000–329,000)	0.321
Lymphocyte (%)	5.9 (1.4–22.4)	5.7 (2.1–48.9)	0.662
INR	1.17 (0.93–5.51)	1.11 (0.98–1.21)	0.065
Albumin (g/dL)	3.1 (2.5–3.9)	3.2 (2.9–3.9)	0.140
Total bilirubin (mg/dL)	2.2 (0.4–14.0)	0.7 (0.3–2.1)	<0.001
AST (IU/L)	34 (11–445)	21 (11–37)	0.008
ALT (IU/L)	87 (15–959)	30 (15–277)	0.016
ALP (IU/L)	92 (39–391)	86 (35–121)	0.072
Creatinine (mg/dL)	0.98 (0.25–4.13)	0.82 (0.35–2.17)	0.137
Concentration of FK506 (ng/mL)	6.6 (0.5–16.7)	6.2 (1.4–10.8)	0.586
Time from LT to CMV infection (days)	21 (1–221)	30 (9–53)	0.001
Highest titer of CMV antigenemia	22 (10–462)	24 (12–754)	0.313
Duration of antiviral agents use (days)	12 (8–27)	16 (14–21)	0.076

GCV, ganciclovir; VGCV, valganciclovir; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; LT, liver transplantation; CMV, cytomegalovirus